Abstract
We studied escalating doses of recombinant human interleukin-1β (IL-1β) alone and after a myelosuppressive dose of 5-fluorouracil (5-FU) in patients with gastrointestinal cancer. Transient neutropenia, monocytopenia, and lymphocytopenia were observed followed by a 1.3- to 6.0-fold (mean, 3.46-fold) dose-dependent neutrophil leukocytosis (P
Cite
CITATION STYLE
Crown, J., Jakubowski, A., Kemeny, N., Gordon, M., Gasparetto, C., Wong, G., … Gabrilove, J. (1991). A phase I trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood, 78(6), 1420–1427. https://doi.org/10.1182/blood.v78.6.1420.bloodjournal7861420
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
